In roughly half of all prostate cancer cases among men of European ancestry, a genetic glitch turns a helpful gene called ERG into a tumor driver. For years, scientists couldn't figure out how to stop it — ERG seemed to have no weak spots a drug could grab onto. But researchers at the University of Michigan in Ann Arbor have now found a hidden door into that stubborn protein, opening a potential new path to treat a subset of prostate cancers.
The team, working at the Rogel Cancer Center, discovered a specific pocket inside the ERG protein and built a tiny molecule called PBITE-1 that can wedge itself into that pocket. Think of it like finding a keyhole where scientists previously thought there was only a blank wall. The molecule doesn't destroy ERG directly — instead, it blocks the protein from doing its cancer-spreading work.
To find PBITE-1, the researchers tested more than 1,600 different compounds, like trying thousands of keys in a lock until one finally turned. The molecule latches onto a region called the PNT domain, which helps ERG talk to other proteins that fuel tumor growth. In lab tests using human prostate cancer cells and mini-organ models, PBITE-1 caused cancer cells to die and stopped them from invading nearby tissue.
Current prostate cancer treatments try to block testosterone from feeding the tumor, but tumors often find ways around those drugs, and the side effects can be rough. By targeting ERG directly instead, doctors might one day be able to treat a specific group of patients more precisely — like choosing the right tool for a specific job rather than using the same blunt instrument for every case.
"This work shows that instead of treating all prostate cancer as one disease, we have the potential to personalize therapy for subtypes of prostate cancer," said Dr. Arul Chinnaiyan, a professor of pathology who originally discovered the ERG gene fusion connection nearly two decades ago. He was part of the team that first identified this genetic glitch as a cancer driver back in 2005.
The findings appeared in the journal Proceedings of the National Academy of Sciences. Researchers caution that PBITE-1 is still just a lab tool — it's not ready to become a medicine for patients yet. But the discovery proves that ERG, once considered impossible to drug, actually has a vulnerability. And that's the kind of breakthrough that gives scientists a map forward.
"It is exciting that we now have a path forward to target ERG in prostate cancer," Chinnaiyan said. The next steps will involve figuring out how to turn this research probe into something that could someday help people.